Scarica l'app Stockscreener
5.05
1.30%
0.06
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
Prelude Therapeutics Hits New 52-Week High of $5.67, Up 527.79% - MarketsMojo
Citizens reiterates Prelude Therapeutics stock rating on IND filing By Investing.com - Investing.com Canada
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2500 Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell 2000 Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2000 Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 3000E Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell Microcap Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Small Cap Completeness Index - marketscreener.com
MapLight Therapeutics appoints two directors to board - Investing.com UK
MapLight Therapeutics appoints two directors to board By Investing.com - Investing.com India
Prelude Therapeutics Inc (PRLD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Prelude Therapeutics (PRLD) Edges Lower as Stock Tests Key Support LevelADD Alert - dars.gov.et
PRLD Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Prelude Therapeutics Inc (PRLD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Prelude Therapeutics Inc (PRLD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prelude Therapeutics Inc (PRLD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Prelude Therapeutics Inc (PRLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prelude Therapeutics Inc (PRLD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Prelude Therapeutics Inc (PRLD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prelude Therapeutics Inc (PRLD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Prelude Therapeutics Inc (PRLD) Institutional Confidence - TradingKey
PRLD Q1 2026 Earnings: EPS Beat Drives Strong Stock ReactionEPS Growth Rate - newsline.com
Market Sentiment Around Loss-Making Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Moomoo
PRLD Q1 2026 Earnings: Narrower Net Loss Beats EstimatesNegative Surprise Momentum - newsline.com
[Form 4] Prelude Therapeutics Inc Insider Trading Activity - Stock Titan
Director at Prelude Therapeutics (PRLD) awarded 38,000 stock options - Stock Titan
Prelude Therapeutics (PRLD) director receives 38,000 stock options at $3.94 strike - Stock Titan
Prelude Therapeutics (PRLD) shareholders back directors, auditor and say-on-pay - Stock Titan
PRLD: All director, auditor, and executive compensation proposals were approved by shareholder vote - TradingView
PRLD: All proposals passed, directors elected, auditor ratified, and no shareholder questions submitted - TradingView
PRLD Stock Price, Quote & Chart | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill
Prelude Therapeutics Rises Pre-Market With Focus on Two Cancer Drugs - Bez Kabli
Prelude Therapeutics Reports Earnings and Advances Precision Oncology Pipeline - asatunews.co.id
Prelude Therapeutics Reports First Quarter Financial Results and Pipeline Expansion - HarianBasis.co
Goldman Sachs Initiates Coverage on Prelude Therapeutics: What It Could Mean for InvestorsEPS Growth Report - newsline.com
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD) - Yahoo Finance
Prelude Therapeutics Drops 5.5% as Biotech Sector Faces Headwinds – Key Support Levels in FocusBollinger Squeeze - The Legal Advocate
PRLDPrelude Therapeutics Inc Stock Price and Quote - Finviz
Prelude Therapeutics (PRLD) Extends Gains: Support Holds, Resistance in FocusFear Greed Index - The Legal Advocate
PRLD Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesOne-Time Gain Impact - newsline.com
Prelude Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update - geneonline.com
Prelude Therapeutics: Current Cash Runway Into 2Q 2028 >PRLD - Moomoo
New PROTACs reported in Prelude Therapeutics patent - BioWorld News
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Sahm
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Goldman Sachs initiates Prelude Therapeutics stock coverage as Early-Stage Biotech - Investing.com India
Prelude Therapeutics (PRLD) price target increased by 11.49% to 7.01 - MSN
Prelude Therapeutics (PRLD) Losses Narrow In Q1 2026 Challenging Bearish Narratives - Sahm
TradingKey - TradingKey
Jefferies raises Prelude Therapeutics stock price target on pipeline progress By Investing.com - Investing.com Australia
Prelude (PRLD) Reports Progress on Strategic Initiatives and Cas - GuruFocus
Prelude Therapeutics Reports Q1 2026 Results, Advances Precision Oncology Pipeline and Extends Cash Runway to 2028 - Minichart
Prelude Therapeutics (NASDAQ:PRLD) Reports Narrower Quarterly Loss, Shares Rise on Cash Runway Extension - ChartMill
Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary - TradingView
Prelude Therapeutics Initiates Phase 1 Study of PRT12396 and Provides R&D Pipeline Update - Quiver Quantitative
Prelude Therapeutics Q1 net loss narrows as expenses fall - TradingView
Prelude Therapeutics (NASDAQ: PRLD) trims Q1 2026 loss and extends cash runway to 2028 - Stock Titan
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Weekly Voice
Prelude Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet - Yahoo Finance
Prelude Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
PRLD Initiates Coverage On Prelude Therapeutics -- Price Target Announced at $9.00 - GuruFocus
1.16%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):